Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study
The aim of the study was to evaluate efficacy and tolerability of two different fixed combinations of an angiotensin-converting enzyme inhibitor and a diuretic: delapril+indapamide (D+I) and captopril+hydrochlorothiazide (C+H) administered for 6 months to patients with mild to moderate essential hyp...
Gespeichert in:
| Veröffentlicht in: | Journal of human hypertension 2003-02, Vol.17 (2), p.139-146 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 146 |
|---|---|
| container_issue | 2 |
| container_start_page | 139 |
| container_title | Journal of human hypertension |
| container_volume | 17 |
| creator | Rosei, E A Rizzoni, D |
| description | The aim of the study was to evaluate efficacy and tolerability of two different fixed combinations of an angiotensin-converting enzyme inhibitor and a diuretic: delapril+indapamide (D+I) and captopril+hydrochlorothiazide (C+H) administered for 6 months to patients with mild to moderate essential hypertension. In all, 96 centres participated in this randomised, parallel groups, controlled study. A total of 829 patients with uncomplicated mild to moderate hypertension were randomised, and 790 were eligible for the analysis of efficacy (intention to treat). Patients of both sexes, aged 18–75 years, newly diagnosed or untreated during the last month were included in the study if their diastolic blood pressure (DBP) was ⩾95 and ⩽114 mmHg. The starting doses of the drugs were delapril 30 mg+indapamide 1.25 mg tablets o.d. or captopril 50 mg+hydrolchlorothiazide 15 mg tablets o.d. After a 1-month treatment period, nonresponders (DBP >90 mmHg, or decrease in DBP |
| doi_str_mv | 10.1038/sj.jhh.1001514 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2640575890</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A183319390</galeid><sourcerecordid>A183319390</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-b110904dcc5d04a07eb4230df2466ed5f7ea6af72241c268e2b4c2d254932ad73</originalsourceid><addsrcrecordid>eNp1kk1vFDEMhkcIREvhyhFFIDh1t0kmmQ9uVVU-pEpc4DzyJJ5OVpnJkmSQ9t_x0_B2Fy0cerIlP37fOHZRvBZ8LXjZXKXNejOOlHOhhXpSnAtVVyutZf20OOet5qtWKn5WvEhpQwwVm-fFmZC6VnVbnhe_b3-BXyC7MLMwsDwiw2FwBsyOwWxZDh4j9M67vPsLmDD1bj70WPSwjc6zrV8Sc7OFLUzOIqUPbI4IecI575sn5_eKbAqWRDNZpUQlB56Nuy3GjHMi0Y8MWCTzMLmE9pJNi8_OEBjxkswpBu_RspQXu3tZPBvAJ3x1jBfFj0-332--rO6-ff56c323MqrWedULwVuurDHacgW8xl7JkttBqqpCq4caoYKhllIJI6sGZa-MtFKrtpRg6_KieHfQ3cbwc8GUu01Y4kyWnawU17VuWk7U20cp0bYNV2V1kroHj52bh5AjGBrWdNeiKUvRlg9SH_6hRgSfxxT8sv_29D-4PoAmhpQiDh0tZIK46wTv9kfSpU1HR9Idj4Qa3hwfufQT2hN-vAoC3h8BSAb8QMswLp04VTVcN4K4qwOXqDTfYzxN-4j1H9N311A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219980436</pqid></control><display><type>article</type><title>Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rosei, E A ; Rizzoni, D</creator><creatorcontrib>Rosei, E A ; Rizzoni, D ; DIMS II (Delapril-Indapamide Multicenter Study II) ; on behalf of DIMS II (Delapril–Indapamide Multicenter Study II)</creatorcontrib><description>The aim of the study was to evaluate efficacy and tolerability of two different fixed combinations of an angiotensin-converting enzyme inhibitor and a diuretic: delapril+indapamide (D+I) and captopril+hydrochlorothiazide (C+H) administered for 6 months to patients with mild to moderate essential hypertension. In all, 96 centres participated in this randomised, parallel groups, controlled study. A total of 829 patients with uncomplicated mild to moderate hypertension were randomised, and 790 were eligible for the analysis of efficacy (intention to treat). Patients of both sexes, aged 18–75 years, newly diagnosed or untreated during the last month were included in the study if their diastolic blood pressure (DBP) was ⩾95 and ⩽114 mmHg. The starting doses of the drugs were delapril 30 mg+indapamide 1.25 mg tablets o.d. or captopril 50 mg+hydrolchlorothiazide 15 mg tablets o.d. After a 1-month treatment period, nonresponders (DBP >90 mmHg, or decrease in DBP <10 mmHg) had the daily dose increased to either delapril 30 mg+indapamide 2.5 mg or captopril 50 mg+hydrochlorothiazide 25 mg tablets for a further 5 months. The primary assessment of antihypertensive efficacy was the percentage of patients who responded after a 6-month drug treatment. The responder rates were 72.6% with D+I and 62.9% with C+H (
P
=0.004 between treatments) after 60 days of treatment, and 92.6% in the D+I and 85.2% in the C+H (
P
<0.001 between treatments) at the end of the treatment period. The final value of systolic blood pressure was 134.5±13.1 mmHg with D+I and 138.3±14.0 mmHg with C+H (
P
<0.001 between treatments). At the final visit, DBP was 84.57±7.0 mmHg in the D+I group and 85.57±8.0 mmHg in the control group (
P
=0.017 between treatments). In all, 11 patients in the D+I group and 19 patients in the C+H group were withdrawn from the study because of adverse events. In all, 30 patients (7.6%) with D+I and 32 patients (8.1%) with C+H experienced adverse events. In conclusion, D+I was more effective than C+H in terms of overall reduction in blood pressure and response rate. Greater efficacy was obtained without any increase in adverse effects, since both treatments were equally well tolerated.</description><identifier>ISSN: 0950-9240</identifier><identifier>EISSN: 1476-5527</identifier><identifier>DOI: 10.1038/sj.jhh.1001514</identifier><identifier>PMID: 12574793</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject><![CDATA[ACE inhibitors ; Adolescent ; Adult ; Aged ; Angiotensin ; Angiotensin-converting enzyme inhibitors ; Angiotensin-Converting Enzyme Inhibitors - administration & dosage ; Angiotensin-Converting Enzyme Inhibitors - adverse effects ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Antihypertensive agents ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - therapeutic use ; Antihypertensives ; Biological and medical sciences ; Blood pressure ; Captopril - administration & dosage ; Captopril - adverse effects ; Captopril - therapeutic use ; Cardiovascular system ; Diuretics ; Dosage and administration ; Drug Combinations ; Drug therapy ; Epidemiology ; Essential hypertension ; Female ; Health Administration ; Humans ; Hydrochlorothiazide ; Hydrochlorothiazide - administration & dosage ; Hydrochlorothiazide - adverse effects ; Hydrochlorothiazide - therapeutic use ; Hypertension ; Hypertension - drug therapy ; Indans - administration & dosage ; Indans - adverse effects ; Indans - therapeutic use ; Indapamide ; Indapamide - administration & dosage ; Indapamide - adverse effects ; Indapamide - therapeutic use ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; original-article ; Patients ; Peptidyl-dipeptidase A ; Pharmacology. Drug treatments ; Physiological aspects ; Public Health ; Severity of Illness Index ; Tablets]]></subject><ispartof>Journal of human hypertension, 2003-02, Vol.17 (2), p.139-146</ispartof><rights>Springer Nature Limited 2003</rights><rights>2003 INIST-CNRS</rights><rights>COPYRIGHT 2003 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Feb 2003</rights><rights>Nature Publishing Group 2003.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-b110904dcc5d04a07eb4230df2466ed5f7ea6af72241c268e2b4c2d254932ad73</citedby><cites>FETCH-LOGICAL-c475t-b110904dcc5d04a07eb4230df2466ed5f7ea6af72241c268e2b4c2d254932ad73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.jhh.1001514$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.jhh.1001514$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14680581$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12574793$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosei, E A</creatorcontrib><creatorcontrib>Rizzoni, D</creatorcontrib><creatorcontrib>DIMS II (Delapril-Indapamide Multicenter Study II)</creatorcontrib><creatorcontrib>on behalf of DIMS II (Delapril–Indapamide Multicenter Study II)</creatorcontrib><title>Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study</title><title>Journal of human hypertension</title><addtitle>J Hum Hypertens</addtitle><addtitle>J Hum Hypertens</addtitle><description>The aim of the study was to evaluate efficacy and tolerability of two different fixed combinations of an angiotensin-converting enzyme inhibitor and a diuretic: delapril+indapamide (D+I) and captopril+hydrochlorothiazide (C+H) administered for 6 months to patients with mild to moderate essential hypertension. In all, 96 centres participated in this randomised, parallel groups, controlled study. A total of 829 patients with uncomplicated mild to moderate hypertension were randomised, and 790 were eligible for the analysis of efficacy (intention to treat). Patients of both sexes, aged 18–75 years, newly diagnosed or untreated during the last month were included in the study if their diastolic blood pressure (DBP) was ⩾95 and ⩽114 mmHg. The starting doses of the drugs were delapril 30 mg+indapamide 1.25 mg tablets o.d. or captopril 50 mg+hydrolchlorothiazide 15 mg tablets o.d. After a 1-month treatment period, nonresponders (DBP >90 mmHg, or decrease in DBP <10 mmHg) had the daily dose increased to either delapril 30 mg+indapamide 2.5 mg or captopril 50 mg+hydrochlorothiazide 25 mg tablets for a further 5 months. The primary assessment of antihypertensive efficacy was the percentage of patients who responded after a 6-month drug treatment. The responder rates were 72.6% with D+I and 62.9% with C+H (
P
=0.004 between treatments) after 60 days of treatment, and 92.6% in the D+I and 85.2% in the C+H (
P
<0.001 between treatments) at the end of the treatment period. The final value of systolic blood pressure was 134.5±13.1 mmHg with D+I and 138.3±14.0 mmHg with C+H (
P
<0.001 between treatments). At the final visit, DBP was 84.57±7.0 mmHg in the D+I group and 85.57±8.0 mmHg in the control group (
P
=0.017 between treatments). In all, 11 patients in the D+I group and 19 patients in the C+H group were withdrawn from the study because of adverse events. In all, 30 patients (7.6%) with D+I and 32 patients (8.1%) with C+H experienced adverse events. In conclusion, D+I was more effective than C+H in terms of overall reduction in blood pressure and response rate. Greater efficacy was obtained without any increase in adverse effects, since both treatments were equally well tolerated.</description><subject>ACE inhibitors</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Angiotensin</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</subject><subject>Angiotensin-Converting Enzyme Inhibitors - adverse effects</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Antihypertensive agents</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Antihypertensives</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Captopril - administration & dosage</subject><subject>Captopril - adverse effects</subject><subject>Captopril - therapeutic use</subject><subject>Cardiovascular system</subject><subject>Diuretics</subject><subject>Dosage and administration</subject><subject>Drug Combinations</subject><subject>Drug therapy</subject><subject>Epidemiology</subject><subject>Essential hypertension</subject><subject>Female</subject><subject>Health Administration</subject><subject>Humans</subject><subject>Hydrochlorothiazide</subject><subject>Hydrochlorothiazide - administration & dosage</subject><subject>Hydrochlorothiazide - adverse effects</subject><subject>Hydrochlorothiazide - therapeutic use</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Indans - administration & dosage</subject><subject>Indans - adverse effects</subject><subject>Indans - therapeutic use</subject><subject>Indapamide</subject><subject>Indapamide - administration & dosage</subject><subject>Indapamide - adverse effects</subject><subject>Indapamide - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>original-article</subject><subject>Patients</subject><subject>Peptidyl-dipeptidase A</subject><subject>Pharmacology. Drug treatments</subject><subject>Physiological aspects</subject><subject>Public Health</subject><subject>Severity of Illness Index</subject><subject>Tablets</subject><issn>0950-9240</issn><issn>1476-5527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kk1vFDEMhkcIREvhyhFFIDh1t0kmmQ9uVVU-pEpc4DzyJJ5OVpnJkmSQ9t_x0_B2Fy0cerIlP37fOHZRvBZ8LXjZXKXNejOOlHOhhXpSnAtVVyutZf20OOet5qtWKn5WvEhpQwwVm-fFmZC6VnVbnhe_b3-BXyC7MLMwsDwiw2FwBsyOwWxZDh4j9M67vPsLmDD1bj70WPSwjc6zrV8Sc7OFLUzOIqUPbI4IecI575sn5_eKbAqWRDNZpUQlB56Nuy3GjHMi0Y8MWCTzMLmE9pJNi8_OEBjxkswpBu_RspQXu3tZPBvAJ3x1jBfFj0-332--rO6-ff56c323MqrWedULwVuurDHacgW8xl7JkttBqqpCq4caoYKhllIJI6sGZa-MtFKrtpRg6_KieHfQ3cbwc8GUu01Y4kyWnawU17VuWk7U20cp0bYNV2V1kroHj52bh5AjGBrWdNeiKUvRlg9SH_6hRgSfxxT8sv_29D-4PoAmhpQiDh0tZIK46wTv9kfSpU1HR9Idj4Qa3hwfufQT2hN-vAoC3h8BSAb8QMswLp04VTVcN4K4qwOXqDTfYzxN-4j1H9N311A</recordid><startdate>20030201</startdate><enddate>20030201</enddate><creator>Rosei, E A</creator><creator>Rizzoni, D</creator><general>Nature Publishing Group UK</general><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20030201</creationdate><title>Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study</title><author>Rosei, E A ; Rizzoni, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-b110904dcc5d04a07eb4230df2466ed5f7ea6af72241c268e2b4c2d254932ad73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>ACE inhibitors</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Angiotensin</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</topic><topic>Angiotensin-Converting Enzyme Inhibitors - adverse effects</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Antihypertensive agents</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Antihypertensives</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Captopril - administration & dosage</topic><topic>Captopril - adverse effects</topic><topic>Captopril - therapeutic use</topic><topic>Cardiovascular system</topic><topic>Diuretics</topic><topic>Dosage and administration</topic><topic>Drug Combinations</topic><topic>Drug therapy</topic><topic>Epidemiology</topic><topic>Essential hypertension</topic><topic>Female</topic><topic>Health Administration</topic><topic>Humans</topic><topic>Hydrochlorothiazide</topic><topic>Hydrochlorothiazide - administration & dosage</topic><topic>Hydrochlorothiazide - adverse effects</topic><topic>Hydrochlorothiazide - therapeutic use</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Indans - administration & dosage</topic><topic>Indans - adverse effects</topic><topic>Indans - therapeutic use</topic><topic>Indapamide</topic><topic>Indapamide - administration & dosage</topic><topic>Indapamide - adverse effects</topic><topic>Indapamide - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>original-article</topic><topic>Patients</topic><topic>Peptidyl-dipeptidase A</topic><topic>Pharmacology. Drug treatments</topic><topic>Physiological aspects</topic><topic>Public Health</topic><topic>Severity of Illness Index</topic><topic>Tablets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosei, E A</creatorcontrib><creatorcontrib>Rizzoni, D</creatorcontrib><creatorcontrib>DIMS II (Delapril-Indapamide Multicenter Study II)</creatorcontrib><creatorcontrib>on behalf of DIMS II (Delapril–Indapamide Multicenter Study II)</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Journal of human hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosei, E A</au><au>Rizzoni, D</au><aucorp>DIMS II (Delapril-Indapamide Multicenter Study II)</aucorp><aucorp>on behalf of DIMS II (Delapril–Indapamide Multicenter Study II)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study</atitle><jtitle>Journal of human hypertension</jtitle><stitle>J Hum Hypertens</stitle><addtitle>J Hum Hypertens</addtitle><date>2003-02-01</date><risdate>2003</risdate><volume>17</volume><issue>2</issue><spage>139</spage><epage>146</epage><pages>139-146</pages><issn>0950-9240</issn><eissn>1476-5527</eissn><abstract>The aim of the study was to evaluate efficacy and tolerability of two different fixed combinations of an angiotensin-converting enzyme inhibitor and a diuretic: delapril+indapamide (D+I) and captopril+hydrochlorothiazide (C+H) administered for 6 months to patients with mild to moderate essential hypertension. In all, 96 centres participated in this randomised, parallel groups, controlled study. A total of 829 patients with uncomplicated mild to moderate hypertension were randomised, and 790 were eligible for the analysis of efficacy (intention to treat). Patients of both sexes, aged 18–75 years, newly diagnosed or untreated during the last month were included in the study if their diastolic blood pressure (DBP) was ⩾95 and ⩽114 mmHg. The starting doses of the drugs were delapril 30 mg+indapamide 1.25 mg tablets o.d. or captopril 50 mg+hydrolchlorothiazide 15 mg tablets o.d. After a 1-month treatment period, nonresponders (DBP >90 mmHg, or decrease in DBP <10 mmHg) had the daily dose increased to either delapril 30 mg+indapamide 2.5 mg or captopril 50 mg+hydrochlorothiazide 25 mg tablets for a further 5 months. The primary assessment of antihypertensive efficacy was the percentage of patients who responded after a 6-month drug treatment. The responder rates were 72.6% with D+I and 62.9% with C+H (
P
=0.004 between treatments) after 60 days of treatment, and 92.6% in the D+I and 85.2% in the C+H (
P
<0.001 between treatments) at the end of the treatment period. The final value of systolic blood pressure was 134.5±13.1 mmHg with D+I and 138.3±14.0 mmHg with C+H (
P
<0.001 between treatments). At the final visit, DBP was 84.57±7.0 mmHg in the D+I group and 85.57±8.0 mmHg in the control group (
P
=0.017 between treatments). In all, 11 patients in the D+I group and 19 patients in the C+H group were withdrawn from the study because of adverse events. In all, 30 patients (7.6%) with D+I and 32 patients (8.1%) with C+H experienced adverse events. In conclusion, D+I was more effective than C+H in terms of overall reduction in blood pressure and response rate. Greater efficacy was obtained without any increase in adverse effects, since both treatments were equally well tolerated.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>12574793</pmid><doi>10.1038/sj.jhh.1001514</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-9240 |
| ispartof | Journal of human hypertension, 2003-02, Vol.17 (2), p.139-146 |
| issn | 0950-9240 1476-5527 |
| language | eng |
| recordid | cdi_proquest_journals_2640575890 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | ACE inhibitors Adolescent Adult Aged Angiotensin Angiotensin-converting enzyme inhibitors Angiotensin-Converting Enzyme Inhibitors - administration & dosage Angiotensin-Converting Enzyme Inhibitors - adverse effects Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antihypertensive agents Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Antihypertensives Biological and medical sciences Blood pressure Captopril - administration & dosage Captopril - adverse effects Captopril - therapeutic use Cardiovascular system Diuretics Dosage and administration Drug Combinations Drug therapy Epidemiology Essential hypertension Female Health Administration Humans Hydrochlorothiazide Hydrochlorothiazide - administration & dosage Hydrochlorothiazide - adverse effects Hydrochlorothiazide - therapeutic use Hypertension Hypertension - drug therapy Indans - administration & dosage Indans - adverse effects Indans - therapeutic use Indapamide Indapamide - administration & dosage Indapamide - adverse effects Indapamide - therapeutic use Male Medical sciences Medicine Medicine & Public Health Middle Aged original-article Patients Peptidyl-dipeptidase A Pharmacology. Drug treatments Physiological aspects Public Health Severity of Illness Index Tablets |
| title | Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A11%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20the%20efficacy%20and%20tolerability%20of%20the%20combination%20delapril%20plus%20indapamide%20in%20the%20treatment%20of%20mild%20to%20moderate%20essential%20hypertension:%20a%20randomised,%20multicentre,%20controlled%20study&rft.jtitle=Journal%20of%20human%20hypertension&rft.au=Rosei,%20E%20A&rft.aucorp=DIMS%20II%20(Delapril-Indapamide%20Multicenter%20Study%20II)&rft.date=2003-02-01&rft.volume=17&rft.issue=2&rft.spage=139&rft.epage=146&rft.pages=139-146&rft.issn=0950-9240&rft.eissn=1476-5527&rft_id=info:doi/10.1038/sj.jhh.1001514&rft_dat=%3Cgale_proqu%3EA183319390%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219980436&rft_id=info:pmid/12574793&rft_galeid=A183319390&rfr_iscdi=true |